202 related articles for article (PubMed ID: 32936431)
1. Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation.
Buday L; Vas V
Cancer Metastasis Rev; 2020 Dec; 39(4):1067-1073. PubMed ID: 32936431
[TBL] [Abstract][Full Text] [Related]
2. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
[TBL] [Abstract][Full Text] [Related]
3. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
4. Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation.
Kano Y; Gebregiworgis T; Marshall CB; Radulovich N; Poon BPK; St-Germain J; Cook JD; Valencia-Sama I; Grant BMM; Herrera SG; Miao J; Raught B; Irwin MS; Lee JE; Yeh JJ; Zhang ZY; Tsao MS; Ikura M; Ohh M
Nat Commun; 2019 Jan; 10(1):224. PubMed ID: 30644389
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor stimulation of GTPase-activating protein tyrosine phosphorylation in control and c-H-ras-expressing NIH 3T3 cells correlates with p21ras activation.
Molloy CJ; Fleming TP; Bottaro DP; Cuadrado A; Aaronson SA
Mol Cell Biol; 1992 Sep; 12(9):3903-9. PubMed ID: 1508192
[TBL] [Abstract][Full Text] [Related]
6. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
[TBL] [Abstract][Full Text] [Related]
7. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
[TBL] [Abstract][Full Text] [Related]
8. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
Jiang L; Xu W; Chen Y; Zhang Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
[TBL] [Abstract][Full Text] [Related]
9. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
[TBL] [Abstract][Full Text] [Related]
10. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
11. The effects of mutant Ras proteins on the cell signalome.
Takács T; Kudlik G; Kurilla A; Szeder B; Buday L; Vas V
Cancer Metastasis Rev; 2020 Dec; 39(4):1051-1065. PubMed ID: 32648136
[TBL] [Abstract][Full Text] [Related]
12. Sprouty2-modulated Kras signaling rescues Shp2 deficiency during lens and lacrimal gland development.
Pan Y; Carbe C; Powers A; Feng GS; Zhang X
Development; 2010 Apr; 137(7):1085-93. PubMed ID: 20215346
[TBL] [Abstract][Full Text] [Related]
13. A complex of Grb2 adaptor protein, Sos exchange factor, and a 36-kDa membrane-bound tyrosine phosphoprotein is implicated in ras activation in T cells.
Buday L; Egan SE; Rodriguez Viciana P; Cantrell DA; Downward J
J Biol Chem; 1994 Mar; 269(12):9019-23. PubMed ID: 7510700
[TBL] [Abstract][Full Text] [Related]
14. Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown.
Srikar R; Suresh D; Zambre A; Taylor K; Chapman S; Leevy M; Upendran A; Kannan R
Sci Rep; 2016 Aug; 6():30245. PubMed ID: 27530552
[TBL] [Abstract][Full Text] [Related]
15. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
16. Internalized epidermal growth factor receptors participate in the activation of p21(ras) in fibroblasts.
Haugh JM; Huang AC; Wiley HS; Wells A; Lauffenburger DA
J Biol Chem; 1999 Nov; 274(48):34350-60. PubMed ID: 10567412
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
[TBL] [Abstract][Full Text] [Related]
18. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
[No Abstract] [Full Text] [Related]
19. Thyrotropin-releasing hormone stimulates MAP kinase activity in GH3 cells by divergent pathways. Evidence of a role for early tyrosine phosphorylation.
Ohmichi M; Sawada T; Kanda Y; Koike K; Hirota K; Miyake A; Saltiel AR
J Biol Chem; 1994 Feb; 269(5):3783-8. PubMed ID: 7508919
[TBL] [Abstract][Full Text] [Related]
20. Signal transduction pathways from insulin receptors to Ras. Analysis by mutant insulin receptors.
Yonezawa K; Ando A; Kaburagi Y; Yamamoto-Honda R; Kitamura T; Hara K; Nakafuku M; Okabayashi Y; Kadowaki T; Kaziro Y
J Biol Chem; 1994 Feb; 269(6):4634-40. PubMed ID: 7508445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
